Log in

CYAD Celyad Oncology SA EURONEXT · Belgium

Celyad Oncology SA (CYAD) news

Celyad Oncology SA is a public biotech or pharmaceutical company listed on EURONEXT under the ticker CYAD, recorded under Belgium. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Celyad Oncology SA news

We have not published a story on Celyad Oncology SA yet. When there is news, it will appear here.

Questions about Celyad Oncology SA

What is the ticker symbol of Celyad Oncology SA?

Celyad Oncology SA trades under the ticker CYAD on EURONEXT.

Where is Celyad Oncology SA listed?

Celyad Oncology SA is listed on EURONEXT. Our directory also records these other listings: LSE:0QFK.

Which country or territory is Celyad Oncology SA listed under?

Our directory records Celyad Oncology SA under Belgium.

What does Celyad Oncology SA do?

Our directory classifies Celyad Oncology SA as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Celyad Oncology SA?

The ISIN recorded for Celyad Oncology SA is BE0974260896.

Does aibio.space cover Celyad Oncology SA?

aibio.space lists Celyad Oncology SA among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Celyad Oncology SA?

Companies in our directory listed in the same country and business area as Celyad Oncology SA: Lakefront Biotherapeutics, AgomAb Therapeutics NV, European Medical Solutions., bonyf NV, Oxurion NV, Hyloris Pharmaceuticals SA.

Investor discussion: Celyad Oncology SA

Members talk about Celyad Oncology SA (CYAD). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open EURONEXT:CYAD on TradingView.

Listing details

Celyad Oncology SA is a public biotech or pharmaceutical company listed on EURONEXT under the ticker CYAD, recorded under Belgium. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Celyad Oncology SA
Ticker
CYAD
Listing
EURONEXT
Country or territory
Belgium
Business scope
Biotechnology
ISIN
BE0974260896
Other listed symbols
LSE:0QFK
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.